NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Strategy
MSTR
5
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 3.910
- -0.170-4.17%
Close Mar 3 16:00 ET
- 3.990
- +0.080+2.05%
Post 20:01 ET
213.59MMarket Cap5.92P/E (TTM)
4.130High3.880Low383.91KVolume4.130Open4.080Pre Close1.53MTurnover0.86%Turnover Ratio1.32P/E (Static)54.63MShares10.66052wk High0.65P/B174.17MFloat Cap3.88052wk Low--Dividend TTM44.54MShs Float31.910Historical High--Div YieldTTM6.13%Amplitude2.460Historical Low3.979Avg Price1Lot Size
Voyager Therapeutics Stock Forum
Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
Looks like 6 holds the big buy but we shall see. Don't expect it to get much lower.
No comment yet